In order to investigate whether changes in expression levels of Bcl-2 family proteins might correlate with clinical response to venetoclax-containing regimens, we studied PB samples of CLL patients after two cycles of ibrutinib in the context of the HOVON141/VISION clinical trial [21]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.